The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value of an ADC and have receive ample attention. However, the structural element connecting the two –the chemical linker– also plays an essential role in mode-of-action, efficacy, pharmacokinetics and safety profile of an ADC, but is often underappreciated in considerations of ADC design.Chemical Linkers in Antibody–Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety. Ideal for postgraduate students and active researchers in drug discovery and development, this book provides a comprehensive description of linkers used in ADCs (clinical and late preclinical), insight into key quality attributes of linkers for ADCs, and aids the reader in understanding the role of linker chemistry and designing new ADCs.

Antibody-drug conjugates allow for targeted delivery of chemotherapy to tumours, therefore reducing off-target effects for patients.

Creative Biolabs has developed antibody-drug conjugate (ADC) technology to generate precision medicines targeting specific surface antigens to fight diseases.

Vincerx applies a modular approach in the development of antibody–drug conjugates by incorporating novel targeting and safety features. The company’s lead compounds exhibit high efficacies with minimal toxicities that are expected to improve therapeutic windows. Vincerx believes that partners with first-in-class antibodies, clinical stage antibodies or ADCs against promising targets will benefit from Vincerx’s next-generation payload-linker technologies.

Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market, 2019-2030 Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market, 2019-2030 - Market research report and industry analysis - 13084685

Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the…

Novel linker technology may be critical to increasing the potency and effectiveness of ADCs, explains Philipp Spycher, Co-Founder and CEO of Araris Biotech.

/PRNewswire/ -- INTRODUCTION With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013)...

The crux of successful antibody-drug conjugates (ADCs) rests on an indomitable conjugation and linker system that securely attaches a drug payload to an antibody. Linker and conjugation technologies ...

The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.

The targeted delivery of cytotoxic drugs using antibody drug conjugates would not be possible without effective linkers to connect and then release the key chemical and biological materials.

Creative Biolabs has developed several strategies to generate suitable linkers for the conjugation of different antibodies and drugs

Antibody-drug conjugates (ADCs), which combine the specificity, favorable pharmacokinetics, and biodistribution of a monoclonal antibody (mAb) with the cytotoxic potency of a drug, are promising new therapies for cancer. Along with the development of monoclonal antibodies (mAbs) and cytotoxic drugs, …

The lines represent reverberation artifacts of a small wireless insertable cardiac monitor (ICM), also known as an implantable loop recorder (ILR). This particular device is a Medtronic Reveal LINQ insertable cardiac monitoring system. The devi...

Automatically get coupon codes, loyalty Rewards, and better offers from other sellers.